​

Bio-Rad Laboratories (BIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIO Stock Forecast

Bio-Rad Laboratories (BIO) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $400.00, with a high of $400.00 and a low of $400.00. This represents a 12.37% increase from the last price of $355.97.

$250 $280 $310 $340 $370 $400 High: $400 Avg: $400 Low: $400 Last Closed Price: $355.97

BIO Stock Rating

Bio-Rad Laboratories stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

BIO Forecast vs Benchmarks

TypeNameUpside
StockBio-Rad Laboratories12.37%
SectorHealthcare Stocks 25.20%
IndustryMedical Device Stocks6.39%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$400.00
Last Closing Price$355.97$355.97$355.97
Upside/Downside--12.37%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25222--6
Dec, 24222--6
Nov, 24222--6
Oct, 24234--9
Sep, 24234--9
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 01, 2024Patrick DonnellyCitigroup$400.00$338.5818.14%12.37%
Dec 07, 2022RBC Capital$565.00$399.5941.39%58.72%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024RBC CapitalOutperformOutperformhold
Oct 31, 2024CitigroupBuyBuyhold
Oct 01, 2024Wells FargoBuyBuyhold
Oct 01, 2024CitigroupNeutralBuyupgrade
Aug 27, 2024Wells FargoEqual-Weightinitialise
Jun 03, 2024JefferiesHolddowngrade
Apr 03, 2024CitigroupNeutraldowngrade
Dec 07, 2022RBC CapitalOutperforminitialise

Financial Forecast

EPS Forecast

$-150 $-90 $-30 $30 $90 $150 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$128.13$142.61$-121.79$-21.82-----
Avg Forecast$9.81$15.31$14.39$11.48$10.29$11.51$13.08$15.10$17.35
High Forecast$9.74$15.20$14.28$11.40$10.23$11.47$12.99$14.99$17.22
Low Forecast$9.86$15.39$14.50$11.58$10.34$11.54$13.19$15.22$17.49
Surprise %1206.12%831.48%-946.35%-290.07%-----

Revenue Forecast

$0 $600B $1T $2T $2T $3T Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.55B$2.92B$2.80B$2.67T-----
Avg Forecast$2.44B$2.89B$2.82B$2.68B$2.58B$2.65B$2.78B$2.92B$3.07B
High Forecast$2.43B$2.87B$2.80B$2.66B$2.56B$2.64B$2.78B$2.91B$3.05B
Low Forecast$2.45B$2.90B$2.83B$2.69B$2.59B$2.67B$2.78B$2.93B$3.09B
Surprise %4.22%1.27%-0.51%99736.32%-----

Net Income Forecast

$-650B $-510B $-370B $-230B $-90B $50B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.81B$4.25B$-3.63B$-637.32B-----
Avg Forecast$2.89B$2.27B$-2.01B$-637.32M$300.42M$336.13M$382.24M$441.19M$506.78M
High Forecast$2.31B$1.26B$-3.32B$-1.05B$298.67M$335.11M$379.29M$437.79M$503.03M
Low Forecast$3.47B$3.28B$-696.16M$-220.77M$302.16M$337.14M$385.18M$444.58M$510.83M
Surprise %31.73%87.18%80.50%99900.00%-----

BIO Forecast FAQ

Is Bio-Rad Laboratories stock a buy?

Bio-Rad Laboratories stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bio-Rad Laboratories is a favorable investment for most analysts.

What is Bio-Rad Laboratories's price target?

Bio-Rad Laboratories's price target, set by 4 Wall Street analysts, averages $400 over the next 12 months. The price target range spans from $400 at the low end to $400 at the high end, suggesting a potential 12.37% change from the previous close price of $355.97.

How does Bio-Rad Laboratories stock forecast compare to the average forecast of its sector, industry, and investment themes?

Bio-Rad Laboratories stock forecast shows a 12.37% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the medical device stocks industry (6.39%).

What is the breakdown of analyst ratings for Bio-Rad Laboratories over the past three months?

  • January 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Bio-Rad Laboratories’s EPS forecast?

Bio-Rad Laboratories's average annual EPS forecast for its fiscal year ending in December is 10.29 for 2024, a -147.16% decrease from the reported $-21.82 in 2023. The prediction for 2025 is $11.51, $13.08 for 2026, $15.1 for 2027, and $17.35 for 2028.

What is Bio-Rad Laboratories’s revenue forecast?

Bio-Rad Laboratories's average annual revenue forecast for its fiscal year ending in December is $2.58B for 2024, a -99.90% decrease from the reported $2.67T in 2023. The forecast for 2025 is $2.65B, $2.78B for 2026, $2.92B for 2027, and $3.07B for 2028.

What is Bio-Rad Laboratories’s net income forecast?

For its fiscal year ending in December, Bio-Rad Laboratories's average annual net income forecast is $300.42M for 2024, reflecting a -100.05% decrease from the reported $-637B in 2023. The projection for 2025 is $336.13M, $382.24M for 2026, $441.19M for 2027, and $506.78M for 2028.